🔎 Trials Near Me

Home › NCT07226258

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 Injectable for the Treatment of Knee Pain in Patients With Osteoarthritis of the Knee

Who can join

Ages 40 and older · All sexes

Full eligibility criteria
Inclusion Criteria includes:

1. Male or female patients ≥ 40 years of age
2. Body Mass Index (BMI) limits
3. Chronic knee pain resulting from osteoarthritis
4. Kellgren-Lawrence Grade 2 (mild) or Grade 3 (moderate)
5. Baseline KOOS pain
6. Patients taking baseline analgesics
7. Diagnostic nerve block response
8. Compliance with identified study requirements

Exclusion Criteria includes:

1. Non-OA inflammatory arthritis
2. Confounding elements
3. Lower limb amputation.
4. Specified alternate historic treatments
5. Identified underlying physiologic or psychosocial conditions
6. Patient Health Questionnaire
7. Moderate to severe hepatic impairment
8. Moderate to severe renal impairment
9. Identifiable baseline medications
10. Protocol compliance requirements
11. Known allergies or hypersensitivity to identified agents
12. Identified alcohol or drug abuse history
13. Identified underlying physical exam findings: ECG abnormalities or vital sign abnormalities during study screening per investigator assessment
14. Identified underlying abnormal laboratory results

About the study

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.

What is being tested

Sponsor: Saol Therapeutics Inc · Participants: 150 · Started: Nov 7, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07226258

Locations in the U.S.

CaliforniaSutter Neurology and Pain Management, Roseville
Innovative Pain Treatment Solutions, San Diego
ColoradoDBPS Research, LLC, Greenwood Village
District of ColumbiaInternational Spine, Pain & Performance Center, Washington D.C.
FloridaPrime Medical Research, Coral Gables
Conquest Research, LLC, Orlando
Interventional Pain Institute, The Villages
Conquest Research, LLC, Winter Park
MinnesotaMayo Clinic, Rochester
North CarolinaQueen City Clinical Research, PLLC, Charlotte
The Center for Clinical Research, Winston-Salem
OklahomaComprehensive Specialty Care, Edmond
OregonPacific Sports and Spine, Eugene
PennsylvaniaUniversity Orthopedics Center, Altoona
Pain Diagnostics & Interventional Care LLC, Sewickley
South CarolinaMedical University of South Carolina (MUSC), Charleston
PCPMG Clinical Research Unit, LLC, Greenville
TexasLegent Orthopedic and Spine Hospital, Bellaire
Institute of Precision Pain Medicine, Corpus Christi
International Spine, Pain & Performance Center (IPP), Tyler
UtahUniversity of Utah Orthopedic Center, Salt Lake City
VirginiaVirginia iSpine Physicians, PC, Richmond

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.